<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719534</url>
  </required_header>
  <id_info>
    <org_study_id>SZ3703</org_study_id>
    <nct_id>NCT03719534</nct_id>
  </id_info>
  <brief_title>Haplo SCT vs Haplo-cord SCT for Patients With Hematological Disorders</brief_title>
  <official_title>Comparison of Haplo-identical Stem Cell Transplantation Versus Haplo-cord Stem Cell Transplantation for Patients With Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have hematological disorders and will undergo haplo-identical donor stem cell
      transplantation (haplo SCT) are candidates of this trial. Participants will randomized into
      two arms: Arm A will undergo a typical haplo SCT, while Arm B will receive an co-infusion of
      an unrelated cord blood unit (haplo-cord SCT) in addition to Arm A. Overall survival,
      progression-free survival, nonrelapse mortality and cumulative incidence of relapse will be
      recorded and endpoints.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival from SCT</measure>
    <time_frame>3 year post-SCT</time_frame>
    <description>estimated overall survival at 3 year post-SCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival from SCT</measure>
    <time_frame>3 year post-SCT</time_frame>
    <description>estimated progression-free survival at 3 year post-SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of non-relapse mortality from SCT</measure>
    <time_frame>3 year post-SCT</time_frame>
    <description>estimated nonrelapse mortality at 3 year post-SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse from SCT</measure>
    <time_frame>3 year post-SCT</time_frame>
    <description>estimated cumulative incidence of nonrelapse mortality at 3 year post-SCT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Haplo-identical Donor</condition>
  <condition>Cord Blood</condition>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Haplo-SCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>people enrolled in this arm will receive a typical haplo-identical donor SCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haplo-cord SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>people enrolled in this arm will receive a co-infusion of cord blood unit in addition to a typical haplo-identical donor SCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>haplo-SCT</intervention_name>
    <description>SCT will be performed with a haplo-identical donor</description>
    <arm_group_label>Haplo-SCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>haplo-cord SCT</intervention_name>
    <description>Haplo-identical donor SCT will be performed with co-infusion of unrelated cord blood unit</description>
    <arm_group_label>Haplo-cord SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematological disorders and preparing to perform allogeneic stem cell
             transplantation;

          -  Have no available HLA matched donor;

          -  A haplo-identical donor is available for stem cell collection;

          -  An unrelated cord blood unit is available with at least 4/6 matched HLA loci;

          -  ECOG 0-3;

          -  Could understand the written inform consent.

        Exclusion Criteria:

          -  contraindication of stem cell transplantation;

          -  uncontrolled active infection;

          -  sever organ dysfunction (heart, lung, liver, kidney, etc.);

          -  participating other trials with same purpose

          -  refuse to sign written inform consent;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Chen, M.D., Ph.D.</last_name>
    <phone>+86 512 67781856</phone>
    <email>chenjiasuzhou@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Chen, M.D.</last_name>
      <phone>+86 512 6778 1856</phone>
      <email>chenjiasuzhou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

